Compare CASY & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASY | UTHR |
|---|---|---|
| Founded | 1959 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1B | 20.3B |
| IPO Year | N/A | 1999 |
| Metric | CASY | UTHR |
|---|---|---|
| Price | $562.62 | $495.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $581.10 | $495.08 |
| AVG Volume (30 Days) | 318.8K | ★ 469.0K |
| Earning Date | 12-09-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | 13.31 | ★ 16.08 |
| EPS | 16.25 | ★ 26.38 |
| Revenue | ★ $16,969,580,999.00 | $3,128,400,000.00 |
| Revenue This Year | $10.48 | $13.64 |
| Revenue Next Year | $5.60 | $5.78 |
| P/E Ratio | $34.89 | ★ $19.07 |
| Revenue Growth | 13.33 | ★ 13.50 |
| 52 Week Low | $372.09 | $266.98 |
| 52 Week High | $575.98 | $519.99 |
| Indicator | CASY | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 53.03 | 52.94 |
| Support Level | $541.12 | $498.76 |
| Resistance Level | $575.97 | $519.99 |
| Average True Range (ATR) | 13.89 | 10.91 |
| MACD | 0.73 | -1.69 |
| Stochastic Oscillator | 69.85 | 43.56 |
Casey's General Stores Inc serves as convenience store chain with its 2,900 locations, positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two-thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates the majority of its warehousing and distribution processes internally.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.